Prevalence of High-Burden Medical Conditions Among Young and Middle-Aged Adults With Pediatric-Onset Medical Conditions: Findings From US Private and Public Administrative Claims Data by Whitney, Daniel G.
Prevalence of High-Burden Medical Conditions Among 
Young and Middle-Aged Adults With Pediatric-Onset 
Medical Conditions: Findings From US Private and 
Public Administrative Claims Data
Daniel G. Whitney* ID
Abstract
Adults with pediatric-onset medical conditions (POMCs) are susceptible to early development of high-burden medical 
conditions. However, research pertaining to this topic is lacking, which is vital information that could assist in health 
benefit planning and administration. The purpose of this study was to determine the prevalence of high-burden medical 
conditions among privately and publicly insured adults with POMCs, as compared to adults without POMCs, from the 
US. Data from 2016 were extracted from Optum Clinformatics® Data Mart (private insurance) and a random 20% sample 
from Medicare fee-for-service (public insurance). International Classification of Diseases, Tenth Revision, Clinical 
Modification (ICD-10-CM) diagnosis codes were used to identify 18–64-year-old beneficiaries with POMCs, as well as 
several high-burden medical conditions, including pain, fracture, mood affective disorders, anxiety disorders, ischemic 
heart diseases, cerebrovascular diseases, hypertensive and other cardiovascular diseases, type 2 diabetes, osteoporosis, 
osteoarthritis, chronic obstructive pulmonary diseases, liver diseases, and cancer. Privately and publicly insured adults 
with POMCs had higher prevalence of all medical conditions compared to adults without POMCs. Publicly insured 
adults with POMCs had higher prevalence of all medical conditions compared to privately insured adults with POMCs, 
except for the lower prevalence of pain and cancer. When stratified by the category of POMCs (eg, musculoskeletal, 
circulatory), privately and publicly insured groups tended to have higher prevalence of most (private) or all (public) 
medical conditions compared to adults without POMCs. Adults with POMCs have higher prevalence of several high-
burden medical conditions compared to adults without POMCs. This health disparity was present regardless of insurance 
coverage, but was generally more pronounced for public vs. private insured adults with POMCs. 
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Background
Noncommunicable diseases are growing public health issues,1 
and represent a considerable source for early mortality2 and 
economic burden.3 The burden of noncommunicable diseases 
may disproportionally affect populations with disabilities, 
especially if the disability originated in childhood.
Pediatric-onset medical conditions (POMCs) refer to a 
group of congenital or acquired conditions that originate at 
any point from conception through adolescence, and consist of 
impairments in behavioral, emotional, mental, intellectual, or 
physical function, or are associated with altered development 
or abnormal physiological processes. Very little clinical and 
research attention has been given to individuals with POMCs 
as they become adults, despite the anticipated growth of the 
adult population with POMCs.4 Importantly, individuals with 
POMCs have complicated healthcare needs throughout the 
lifespan. This increases risk for early development of high-
burden medical conditions, which refer to conditions that 
lead to high financial cost, excess morbidity, early mortality, 
or poor quality of life, and include pain, fracture, and 
noncommunicable diseases.5-8 Therefore, a comprehensive 
understanding of the clinical epidemiology of high-burden 
medical conditions among young and middle-aged adults 
with POMCs is needed. Such information could inform 
healthcare policy-makers and clinical practice guidelines that 
promote early and cost-effective care for the aging population 
with POMCs. This study sought to inform these efforts by 
providing recent US national level estimates of the prevalence 
of several high-burden medical conditions for adults with 
POMCs that have private or public health insurance, as 
compared to adults without POMCs. We hypothesized that 
adults with POMCs would have higher prevalence of all 
high-burden medical conditions compared to adults without 
POMCs. We also hypothesized that this disparity would be 
greater for publicly insured adults with POMCs than privately 
insured adults with POMCs.
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Methods
Data Sources
Data for this study were extracted from private and public 
administrative claims data from the year 2016. Optum 
Clinformatics® Data Mart Database (OptumInsightTM, Eden 
Prairie, MN, USA) provided de-identified information for 
privately insured beneficiaries (commercial or Medicare 
Advantage plans). A random 20% sample of the Medicare fee-
for-service database provided de-identified information for 
publicly insured beneficiaries. 
Sample Selection
Beneficiaries that were 18 to 64 years of age, had 12 full months 
of continuous enrollment, and had at least one medical service 
utilization in 2016 were included. Medicare beneficiaries 
were excluded if they were covered by Health Maintenance 
Organization plans because of incomplete claims. Medical 
diagnoses of all POMCs and medical conditions were 
identified using the International Classification of Diseases, 
Tenth Revision, Clinical Modification (ICD-10-CM) codes, 
and are presented in Table S1 (see Supplementary file 1). 
A single claim in any position (medical file in Optum; 
inpatient, outpatient, and carrier file in Medicare) for POMCs 
was used to identify these beneficiaries. The single claim-
based definition has shown good accuracy for identifying 
pediatric-onset conditions using administrative claims data, 
with sensitivity of 99% and positive predictive value of 79%.9 
It is not possible to determine if some POMCs developed 
in childhood or adulthood (eg, spinal cord injury) using a 
single year of claims data. Therefore, only conditions with 
known childhood origins were included. These conditions 
were then grouped into the following POMC subcategories: 
musculoskeletal system; neurodevelopmental; circulatory 
system; nervous system; genital organs; other chromosomal 
abnormalities; urinary system; respiratory and digestive 
systems; and malformations of the eye, ear, face, and neck. 
Beneficiaries of private insurance without any medical claims 
for POMCs represented the group without POMCs. The 
group without POMCs were ascertained through Optum to 
enhance representativeness of the sample of adults without 
POMCs, because criteria for enrollment in Medicare under 
65 years of age requires permanent disability. 
Medical Conditions
Prevalent medical conditions were ascertained using the 
same procedure to identify POMCs. Medical conditions were 
selected with guidance from the literature on disease, disability, 
and mortality,1,2,5,10-12 and included pain, all-cause fracture, and 
several noncommunicable diseases: mood affective disorders; 
anxiety disorders; ischemic heart diseases; cerebrovascular 
diseases; hypertensive and other cardiovascular diseases; 
type 2 diabetes mellitus; osteoporosis; osteoarthritis; chronic 
obstructive pulmonary diseases; chronic kidney diseases; 
liver diseases; and malignant cancer anywhere in the body.
Participant Characteristics
Data on age and gender were extracted as they were reported 
in the same manner from Optum and Medicare. Other 
confounding variables were not considered for covariate 
adjustment to limit bias for reasons such as they had not been 
reported in both data sources (eg, education level), they had 
not been reported in the same manner (eg, race), or they had 
missing data on over 20% of the group (eg, income).
Statistical Analysis
All measures were summarized using SAS version 9.4 (SAS 
Institute, Inc., Cary, NC). Data were presented for adults 
without POMCs and with POMCs stratified by insurance 
coverage (private, public). Then, data were presented for 
adults with POMCs after stratifying by each POMC category 
for private and public insured beneficiaries. 95% CIs were 
calculated for the POMC groups. A sensitivity analysis was 
performed to determine prevalence estimates of medical 
conditions, but with the requirement of having at least 2 
claims from separate days for each POMC and medical 
condition category. 
Results
Participant characteristics for adults without POMCs 
(n = 5 415 475) and adults with POMCs that had private 
(n = 121 446) or public (n = 119 654) insurance is presented in 
Table 1. There were differences in the prevalence of POMC 
categories between private and public insurance. Notably, the 
publicly insured group had considerably (>3 times) higher 
prevalence of neurodevelopmental POMCs and considerably 
(>3 times) lower prevalence of POMCs of the genital organs 
compared to the privately insured group.
Prevalence of high-burden medical conditions among 
adults with and without POMCs is presented in Table 2. 
Privately and publicly insured adults with POMCs had higher 
prevalence of all medical conditions compared to adults 
without POMCs. Publicly insured adults with POMCs had 
higher prevalence of all medical conditions compared to 
privately insured adults with POMCs, except for the lower 
prevalence of pain and cancer.
Prevalence of high-burden medical conditions for each of 
the 9 POMC categories is presented in Table 3. Compared 
to adults without POMCs, most categories of POMCs from 
the privately insured group (7 to 9 categories) tended to have 
higher prevalence of all medical conditions. Compared to 
adults without POMCs, most categories of POMCs from the 
publicly insured group (8 to 9 categories) tended to have higher 
prevalence of all medical conditions. Finally, compared to the 
privately insured group of adults with POMCs, the publicly 
insured group had higher prevalence of all high-burden 
medical conditions for each POMC category, except for the 
similar or lower prevalence between neurodevelopmental 
POMCs for cerebrovascular diseases, POMCs of the nervous 
system for pain, ischemic heart diseases, cerebrovascular 
diseases, liver diseases, and cancer, and POMCs of other 
chromosomal abnormalities for pain, liver diseases, and 
cancer.
The results of the sensitivity analysis requiring at least two 
claims from different days for each category of POMCs and 
medical conditions are presented in Table S2 for adults with 
and without POMCs and Table S3 after stratifying by the type 
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Table 1. Characteristics and Prevalence of High-Burden Medical Conditions Among Adults With and Without POMCs
Without POMCs With POMCs With POMCs
Private Insurance
(n = 5 415 475)
Private Insurance
(n = 121 446)
Public Insurance
(n = 119 654)
Descriptive characteristics Point estimate Point estimate Point estimate
Age, mean (SD) 43.8 (12.9) 44.3 (13.6) 46.9 (11.9)
  18-40 years, % 40.3 44.1 30.9
  41-64 years, % 59.7 55.9 69.1
Gender, %
  Female 53.8 55.6 46.8
  Male 46.2 44.4 53.2
POMC categories, %
Musculoskeletal system 27.6 10.8
Neurodevelopmental 14.1 56.7
Circulatory system 20.1 9.4
Nervous system 9.1 18.6
Genital organs 5.1 0.9
Other chromosomal abnormalities 4.5 9.6
Urinary system 10.3 5.9
Respiratory and digestive system 10.0 4.0
Malformation of eye, ear, face, or neck 4.8 2.1
Abbreviations: POMCs, pediatric-onset medical conditions; SD, standard deviation.
Note: Individuals may have more than one POMC and can be represented across multiple POMC categories.
Table 2. Prevalence of High-Burden Medical Conditions Among Adults With and Without POMCs 
Without POMCs With POMCs With POMCs
Private Insurance 
(n = 5 415 475)
Private Insurance 
(n = 121 446)
Public Insurance 
(n = 119 654)
% % (95% CI) % (95% CI)
Pain 30.1 45.2 (44.9, 45.5) 42.6 (42.3, 42.9)
Fracture 2.6 5.2 (5.1, 5.3) 7.8 (7.6, 8.0)
Mood affective disorders 11.0 20.8 (20.6, 21.0) 41.2 (40.9, 41.5)
Anxiety disorders 15.1 25.5 (25.3, 25.7) 37.9 (37.6, 38.2)
Ischemic heart diseases 3.5 8.7 (8.5, 8.9) 11.4 (11.2, 11.6)
Cerebrovascular diseases 1.5 6.3 (6.2, 6.4) 8.6 (8.4, 8.8)
Hypertensive and other cardiovascular diseases 25.4 37.8 (37.5, 38.1) 50.6 (50.3, 50.9)
Type 2 diabetes 10.0 14.5 (14.3, 14.7) 24.9 (24.7, 25.1)
Osteoporosis 1.3 3.4 (3.3, 3.5) 7.4 (7.3, 7.5)
Osteoarthritis 7.7 15.8 (15.6, 16.0) 19.3 (19.1, 19.5)
Chronic obstructive pulmonary disease 0.7 1.8 (1.7, 1.9) 12.0 (11.8, 12.2)
Chronic kidney disease 1.8 6.6 (6.5, 6.7) 11.4 (11.2, 11.6)
Liver diseases 2.9 7.3 (7.2, 7.4) 8.2 (8.0, 8.4)
Cancer 3.8 6.6 (6.5, 6.7) 5.9 (5.8, 6.0)
Abbreviation: POMCs, pediatric-onset medical conditions.
of POMC category (see Supplementary file 1). Interpretations 
were unchanged for adults with and without POMCs. 
Interpretations were largely unchanged for most categories 
of POMCs from the privately and publicly insured group 
compared to controls.
Discussion
The chief finding here is that young and middle-aged adults 
with POMCs had higher prevalence of several high-burden 
medical conditions compared to adults without POMCs. While 
this was evident for both privately and publicly insured adults 
with POMCs, these health disparities were more pronounced 
for the publicly insured group with POMCs. These are critical 
findings, because these high-burden medical conditions 
are major contributors to the global and national burden of 
disease and mortality,2,13-15 and are typically associated with 
advanced aging. Further, many of these high-burden medical 
conditions can be prevented, delayed, or better managed to 
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Table 3. High-Burden Medical Conditions Among Adults (18-64 Years) Stratified by the Category of POMCs
Musculoskeletal System Neurodevelopmental Circulatory System Nervous System Genital Organs Chromosomal 
Abnormalities
Urinary System Respiratory Digestive Systems Eye, Ear, Face, or Neck
Sample size, n
  Private insurance 33 566 17 149 24 393 11 021 6164 5518 12 477 12 190 5811
  Public insurance 12 910 67 791 11 276 22 276 1070 11 431 6998 4744 2454
Pain, % (95% CI)
  Private insurance 63.4 (62.9, 63.9) 27.8 (27.1, 28.5) 39.8 (39.2, 40.4) 46.0 (45.1, 46.9) 31.9 (30.7, 33.1) 27.2 (26.0, 28.4) 47.3 (46.4, 48.2) 45.3 (44.4, 46.2) 34.4 (33.2, 35.6)
  Public insurance 74.1 (73.3, 74.9) 31.8 (31.4, 32.2) 55.2 (54.3, 56.1) 39.1 (38.5, 39.7) 56.7 (53.7, 59.7) 25.7 (24.9, 26.5) 62.8 (61.7, 63.9) 66.6 (65.3, 67.9) 45.1 (43.1, 47.1)
Fracture, % (95% CI)
  Private insurance 7.7 (7.4, 8.0) 4.8 (4.5, 5.1) 4.1 (3.9, 4.3) 5.7 (5.3, 6.1) 2.3 (1.9, 2.7) 3.6 (3.1, 4.1) 4.5 (4.1, 4.9) 4.7 (4.3, 5.1) 3.5 (3.0, 4.0)
  Public insurance 12.2 (11.6, 12.8) 7.3 (7.1, 7.5) 8.6 (8.1, 9.1) 7.5 (7.2, 7.8) 7.9 (6.3, 9.5) 5.2 (4.8, 5.6) 9.0 (8.3, 9.7) 10.1 (9.2, 11.0) 7.5 (6.5, 8.5)
Mood affective disorders, % (95% CI)
  Private insurance 19.2 (18.8, 19.6) 35.4 (34.7, 36.1) 18.3 (17.8, 18.8) 24.7 (23.9, 25.5) 13.5 (12.6, 14.4) 13.7 (12.8, 14.6) 18.8 (18.1, 19.5) 20.6 (19.9, 21.3) 14.5 (13.6, 15.4)
  Public insurance 44.2 (43.3, 45.1) 45.1 (44.7, 45.5) 39.7 (38.8, 40.6) 30.8 (30.2, 31.4) 45.4 (42.4, 48.4) 22.1 (21.3, 22.9) 39.8 (38.7, 40.9) 48.7 (47.3, 50.1) 34.4 (32.5, 36.3)
Anxiety disorders, % (95% CI)
  Private insurance 24.2 (23.7, 24.7) 37.0 (36.3, 37.7) 24.1 (23.6, 24.6) 27.1 (26.3, 27.9) 20.1 (19.1, 21.1) 18.7 (17.7, 19.7) 23.6 (22.9, 24.3) 26.6 (25.8, 27.4) 19.0 (18.0, 20.0)
  Public insurance 42.8 (41.9, 43.7) 39.9 (39.5, 40.3) 39.8 (38.9, 40.7) 29.0 (28.4, 29.6) 44.2 (41.2, 47.2) 23.0 (22.2, 23.8) 39.8 (38.7, 40.9) 49.4 (48.0, 50.8) 31.8 (30.0, 33.6)
Ischemic heart diseases, % (95% CI)
  Private insurance 5.4 (5.2, 5.6) 4.7 (4.4, 5.0) 19.9 (19.4, 20.4) 5.6 (5.2, 6.0) 2.9 (2.5, 3.3) 3.2 (2.7, 3.7) 10.9 (10.4, 11.4) 8.4 (7.9, 8.9) 4.4 (3.9, 4.9)
  Public insurance 14.7 (14.1, 15.3) 6.8 (6.6, 7.0) 33.8 (32.9, 34.7) 5.8 (5.5, 6.1) 14.5 (12.4, 16.6) 4.4 (4.0, 4.8) 26.9 (25.9, 27.9) 21.7 (20.5, 22.9) 11.1 (9.9, 12.3)
Cerebrovascular diseases, % (95% CI)
  Private insurance 3.1 (2.9, 3.3) 6.2 (5.8, 6.6) 15.0 (14.6, 15.4) 7.9 (7.4, 8.4) 1.7 (1.4, 2.0) 2.8 (2.4, 3.2) 5.5 (5.1, 5.9) 4.0 (3.7, 4.3) 2.9 (2.5, 3.3)
  Public insurance 9.0 (8.5, 9.5) 6.2 (6.0, 6.4) 24.7 (23.9, 25.5) 7.7 (7.3, 8.1) 8.6 (6.9, 10.3) 4.3 (3.9, 4.7) 13.7 (12.9, 14.5) 11.9 (11.0, 12.8) 6.1 (5.2, 7.0)
Hypertensive and other cardiovascular diseases, % (95% CI)
  Private insurance 32.2 (31.7, 32.7) 32.3 (31.6, 33.0) 49.0 (48.4, 49.6) 35.8 (34.9, 36.7) 19.5 (18.5, 20.5) 21.1 (20.0, 22.2) 57.7 (56.8, 58.6) 40.1 (39.2, 41.0) 28.8 (27.6, 30.0)
  Public insurance 59.3 (58.5, 60.1) 45.4 (45.0, 45.8) 71.4 (70.6, 72.2) 42.4 (41.8, 43.0) 58.6 (55.6, 61.6) 28.8 (28.0, 29.6) 83.4 (82.5, 84.3) 67.2 (65.9, 68.5) 50.3 (48.3, 52.3)
Type 2 diabetes, % (95% CI)
  Private insurance 12.9 (12.5, 13.3) 16.7 (16.1, 17.3) 15.7 (15.2, 16.2) 12.7 (12.1, 13.3) 7.7 (7.0, 8.4) 11.7 (10.9, 12.5) 18.9 (18.2, 19.6) 15.1 (14.5, 15.7) 14.3 (13.4, 15.2)
  Public insurance 28.9 (28.1, 29.7) 23.0 (22.7, 23.3) 33.5 (32.6, 34.4) 15.5 (15.0, 16.0) 32.2 (29.4, 35.0) 17.2 (16.5, 17.9) 37.1 (36, 38.2) 33.3 (32.0, 34.6) 28.9 (27.1, 30.7)
Whitney
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Osteoporosis, % (95% CI)
  Private insurance 4.0 (3.8, 4.2) 3.1 (2.8, 3.4) 2.9 (2.7, 3.1) 4.3 (3.9, 4.7) 1.0 (0.8, 1.2) 3.6 (3.1, 4.1) 3.6 (3.3, 3.9) 4.4 (4.0, 4.8) 2.2 (1.8, 2.6)
  Public insurance 11.0 (10.5, 11.5) 7.3 (7.1, 7.5) 7.4 (6.9, 7.9) 10.9 (10.5, 11.3) 6.7 (5.2, 8.2) 7.5 (7.0, 8.0) 8.0 (7.4, 8.6) 10.5 (9.6, 11.4) 7.1 (6.1, 8.1)
Osteoarthritis, % (95% CI)
  Private insurance 25.1 (24.6, 25.6) 9.4 (9.0, 9.8) 13.6 (13.2, 14.0) 14.1 (13.5, 14.7) 6.0 (5.4, 6.6) 7.6 (6.9, 8.3) 15.9 (15.3, 16.5) 15.9 (15.3, 16.5) 9.8 (9.0, 10.6)
  Public insurance 40.0 (39.2, 40.8) 13.7 (13.4, 14.0) 26.0 (25.2, 26.8) 15.5 (15.0, 16.0) 26.5 (23.9, 29.1) 12.2 (11.6, 12.8) 29.2 (28.1, 30.3) 32.5 (31.2, 33.8) 20.3 (18.7, 21.9)
Chronic obstructive pulmonary disease, % (95% CI)
  Private insurance 1.4 (1.3, 1.5) 1.2 (1.0, 1.4) 2.6 (2.4, 2.8) 1.6 (1.4, 1.8) 0.7 (0.5, 0.9) 0.9 (0.7, 1.1) 2.4 (2.1, 2.7) 2.7 (2.4, 3.0) 1.1 (0.8, 1.4)
  Public insurance 18.0 (17.3, 18.7) 8.6 (8.4, 8.8) 24.0 (23.2, 24.8) 7.5 (7.2, 7.8) 15.1 (13.0, 17.2) 4.5 (4.1, 4.9) 21.1 (20.1, 22.1) 27.1 (25.8, 28.4) 11.5 (10.2, 12.8)
Chronic kidney disease, % (95% CI)
  Private insurance 3.2 (3.0, 3.4) 5.1 (4.8, 5.4) 6.4 (6.1, 6.7) 4.3 (3.9, 4.7) 2.3 (1.9, 2.7) 4.0 (3.5, 4.5) 27.7 (26.9, 28.5) 5.3 (4.9, 5.7) 3.3 (2.8, 3.8)
  Public insurance 11.6 (11.0, 12.2) 6.7 (6.5, 6.9) 21.5 (20.7, 22.3) 5.7 (5.4, 6.0) 15.5 (13.3, 17.7) 6.8 (6.3, 7.3) 57.2 (56.0, 58.4) 18.2 (17.1, 19.3) 11.3 (10.0, 12.6)
Liver diseases, % (95% CI)
  Private insurance 4.9 (4.7, 5.1) 4.3 (4.0, 4.6) 7.5 (7.2, 7.8) 4.6 (4.2, 5.0) 4.0 (3.5, 4.5) 4.6 (4.0, 5.2) 17.2 (16.5, 17.9) 15.4 (14.8, 16.0) 4.3 (3.8, 4.8)
  Public insurance 10.1 (9.6, 10.6) 5.8 (5.6, 6.0) 13.5 (12.9, 14.1) 5.2 (4.9, 5.5) 12.7 (10.7, 14.7) 5.0 (4.6, 5.4) 22.1 (21.1, 23.1) 22.9 (21.7, 24.1) 7.1 (6.1, 8.1)
Cancer, % (95% CI)
  Private insurance 5.2 (5.0, 5.4) 3.5 (3.2, 3.8) 7.1 (6.8, 7.4) 5.4 (5.0, 5.8) 4.6 (4.1, 5.1) 5.7 (5.1, 6.3) 11.9 (11.3, 12.5) 10.5 (10.0, 11.0) 6.6 (6.0, 7.2)
  Public insurance 7.7 (7.2, 8.2) 4.0 (3.9, 4.1) 9.1 (8.6, 9.6) 4.4 (4.1, 4.7) 10.7 (8.8, 12.6) 3.4 (3.1, 3.7) 14.1 (13.3, 14.9) 13.2 (12.2, 14.2) 7.3 (6.3, 8.3)
Abbreviation: POMCs, pediatric-onset medical conditions.
Note: Individuals may have more than one POMC and can be represented across multiple POMC categories.
Musculoskeletal System Neurodevelopmental Circulatory System Nervous System Genital Organs Chromosomal 
Abnormalities
Urinary System Respiratory Digestive Systems Eye, Ear, Face, or Neck
Table 3. Continued
Whitney
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reduce patient and caregiver burden. Taken together, these 
findings highlight the need for earlier clinical, rehabilitative, 
and healthcare policy efforts to improve awareness and access 
to quality healthcare, such as screening strategies, for these 
populations to allow for earlier detection of these high-
burden medical conditions.
In the current study, we also found that adults with POMCs 
of a particular biological system may be at greater risk of 
high-burden medical conditions of that same biological 
system. Notably, POMCs of the musculoskeletal system 
had the highest prevalence of fracture, osteoporosis, and 
osteoarthritis; POMCs of the circulatory system had the 
highest prevalence of ischemic heart diseases, cerebrovascular 
diseases, and hypertensive and other cardiovascular diseases; 
and POMCs of the urinary system had the highest prevalence 
of chronic kidney diseases. This information could assist 
clinical care for adults with POMCs, by allowing clinicians 
to target preventative and rehabilitation care specific to 
the needs of their patients with POMCs. This information 
could also assist in health benefit planning, by allowing 
administrators to allocate healthcare resources based on the 
POMC demographics of health plans. 
A major strength of the current study is the large sample of 
adults with POMCs from both private and public insurance 
databases, thus enhancing external validity.16 Gathering data 
on clinical populations can be challenging, and little is known 
about the healthful aging process for individuals with POMCs 
across the lifespan. Another major strength of this study is the 
comprehensive assessment of several high-burden medical 
conditions, with many representing major contributors to the 
global and national burden of disease and mortality.2,13-15 The 
present findings are robust and could improve clinical care 
and inform new research examining health disparities and 
healthcare delivery for individuals with POMCs. 
The limitations must be discussed. First, while Optum 
and Medicare databases are nationwide, Optum coverage is 
more predominant in Southern and Western regions of the 
United States, which may bias estimates because of regional 
differences in chronic disease prevalence.17 Second, the 
primary analysis used a single claim to identify beneficiaries 
with POMCs and medical conditions. While validation 
studies have shown that at least 2 claims for a medical 
condition improves ability to identify beneficiaries with that 
medical condition,9,18 single claim-based algorithms have 
been reported to have moderate-to-high positive predictive 
value (~80%) to detect POMCs,9 or specificity up to 96% 
to detect a variety of medical conditions;19,20 however, the 
accuracy of identifying conditions using claims data depends 
on the length of the study period19 and the medical condition 
examined.9,19-21 In light of this, a sensitivity analysis was 
performed that used at least two claims from different days 
to identify all POMCs and medical conditions. The results 
revealed the same conclusions as the primary analysis. When 
taken together, given the short study period of 12 months, the 
selected methodology to identify medical conditions using a 
single claim is likely sufficient to detect that the current data 
is evidence of health disparities among adults with POMCs, as 
compared to adults without POMCs. Third, the present study 
excluded individuals that did not have service utilization in 
2016, which may have biased results. However, these excluded 
individuals that had insurance coverage may be somewhat 
healthy since they did not require a medical encounter in 2016, 
thus potentially biasing results in the present study to be more 
conservative estimates. Fourth, it is not possible using claims-
based data from a single year to determine if certain conditions 
developed in childhood or later in life (eg, spinal cord injury, 
cancer, depression). Fifth, data were from a single year and 
longer study periods and longitudinal research designs could 
provide more robust findings and implications for research, 
practice, and policy. Lastly, the present study presented 
descriptive statistics rather than inferential statistics, and 
therefore did not account for potential confounding factors, 
such as indicators of socioeconomic status. 
Conclusion
Adults with POMCs have higher prevalence of several 
high-burden medical conditions compared to adults 
without POMCs. This health disparity was present for both 
private and public insurance coverage, but was generally 
more pronounced for public vs. private insured adults 
with POMCs. Study findings are critical, because many of 
these high-burden medical conditions are associated with 
advanced aging, and may be prevented, delayed, or better 
managed with adequate clinical knowledge. These findings 
highlight the need for clinical and public health strategies to 
implement earlier detection and preventive medical services 
for noncommunicable diseases and other high-burden 
medical conditions for adult populations with POMCs. Future 
research is needed to examine how these high-burden medical 
condition profiles associate with mortality and quality of life 
for adults with POMCs.
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